Research Study

Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Principal Investigator 
Lorne F. Kastrukoff

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT00676715
Status 
Closed to Recruitment
Study Start/End 
Jun 1, 2012 to Apr 1, 2020
Locations 
UBC Hospital
Name/Title 
Michelle K. Wong, Clinical Trial Coordinator
Phone 
604-822-7949
Email Address 
michelle.w@ubc.ca
Purpose of Study 

This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with RRMS.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.